SCY-635 is an investigational drug.
There have been 14 clinical trials for SCY-635.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 15th 2017.
The most common disease conditions in clinical trials are Candidiasis, Candidiasis, Vulvovaginal, and Candidiasis, Invasive. The leading clinical trial sponsors are Scynexis, Inc., Clinical Network Services (CNS) Pty Ltd, and ethica Clinical Research Inc.
There are one hundred and sixty-eight US patents protecting this investigational drug and two international patents.